Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SIQING FU and KHANDAN KEYOMARSI.
SIQING FU
Connection Strength
0.626
KHANDAN KEYOMARSI
  1. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
    View in: PubMed
    Score: 0.227
  2. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610.
    View in: PubMed
    Score: 0.169
  3. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs. 2018 09; 27(9):741-751.
    View in: PubMed
    Score: 0.169
  4. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398.
    View in: PubMed
    Score: 0.061
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.